Cargando…
SEOM guidelines for the management of Malignant Melanoma 2015
All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiother...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Milan
2015
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689745/ https://www.ncbi.nlm.nih.gov/pubmed/26669314 http://dx.doi.org/10.1007/s12094-015-1450-4 |
| _version_ | 1782406882792570880 |
|---|---|
| author | Berrocal, A. Arance, A. Espinosa, E. Castaño, A. G. Cao, M. G. Larriba, J. L. G. Martín, J. A. L. Márquez, I. Soria, A. Algarra, S. M. |
| author_facet | Berrocal, A. Arance, A. Espinosa, E. Castaño, A. G. Cao, M. G. Larriba, J. L. G. Martín, J. A. L. Márquez, I. Soria, A. Algarra, S. M. |
| author_sort | Berrocal, A. |
| collection | PubMed |
| description | All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams. |
| format | Online Article Text |
| id | pubmed-4689745 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2015 |
| publisher | Springer Milan |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-46897452015-12-31 SEOM guidelines for the management of Malignant Melanoma 2015 Berrocal, A. Arance, A. Espinosa, E. Castaño, A. G. Cao, M. G. Larriba, J. L. G. Martín, J. A. L. Márquez, I. Soria, A. Algarra, S. M. Clin Transl Oncol Clinical Guides in Oncology All melanoma patients must be confirmed histologically and resected according to Breslow. Sentinel node biopsy must be done when tumor is over 1 mm or if less with high-risk factors. Adjuvant therapy with interferon must be offered for patients with high-risk melanoma and in selected cases radiotherapy can be added. Metastatic melanoma treatment is guided by mutational BRAF status. BRAF wild type patients must receive anti-PD1 therapy and BRAF mutated patients BRAF/MEK inhibitors or anti-PD1 therapy. Up to 10 years follow up is recommended for melanoma patients with dermatologic examinations and physical exams. Springer Milan 2015-12-15 2015 /pmc/articles/PMC4689745/ /pubmed/26669314 http://dx.doi.org/10.1007/s12094-015-1450-4 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| spellingShingle | Clinical Guides in Oncology Berrocal, A. Arance, A. Espinosa, E. Castaño, A. G. Cao, M. G. Larriba, J. L. G. Martín, J. A. L. Márquez, I. Soria, A. Algarra, S. M. SEOM guidelines for the management of Malignant Melanoma 2015 |
| title | SEOM guidelines for the management of Malignant Melanoma 2015 |
| title_full | SEOM guidelines for the management of Malignant Melanoma 2015 |
| title_fullStr | SEOM guidelines for the management of Malignant Melanoma 2015 |
| title_full_unstemmed | SEOM guidelines for the management of Malignant Melanoma 2015 |
| title_short | SEOM guidelines for the management of Malignant Melanoma 2015 |
| title_sort | seom guidelines for the management of malignant melanoma 2015 |
| topic | Clinical Guides in Oncology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689745/ https://www.ncbi.nlm.nih.gov/pubmed/26669314 http://dx.doi.org/10.1007/s12094-015-1450-4 |
| work_keys_str_mv | AT berrocala seomguidelinesforthemanagementofmalignantmelanoma2015 AT arancea seomguidelinesforthemanagementofmalignantmelanoma2015 AT espinosae seomguidelinesforthemanagementofmalignantmelanoma2015 AT castanoag seomguidelinesforthemanagementofmalignantmelanoma2015 AT caomg seomguidelinesforthemanagementofmalignantmelanoma2015 AT larribajlg seomguidelinesforthemanagementofmalignantmelanoma2015 AT martinjal seomguidelinesforthemanagementofmalignantmelanoma2015 AT marquezi seomguidelinesforthemanagementofmalignantmelanoma2015 AT soriaa seomguidelinesforthemanagementofmalignantmelanoma2015 AT algarrasm seomguidelinesforthemanagementofmalignantmelanoma2015 |